Cortés, Javier

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology

Cited by 2,532

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchCancer Treatment and Pharmacology

Cited by 2,164

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 1,711

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 1,369

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,006

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 922

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 807

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Bidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 777

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2023) · The Lancet

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 496

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 413

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients

Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 337

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial

Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 72

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Duro-Sánchez, S., Nadal-Serrano, M., Lalinde-Gutiérrez, M., Arenas, E. J., Bernadó Morales, C., Morancho, B., Escorihuela, M., Pérez-Ramos, S., Escrivá-de-Romaní, S., Gandullo-Sánchez, L., et al. (2022) · Cancer Research

HER2/EGFR in Cancer ResearchTelomeres, Telomerase, and Senescence

Cited by 45

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

Shenderov, E., Mallesara, G. H. G., Wysocki, P. J., Xu, W., Ramlau, R., Weickhardt, A. J., Zolnierek, J., Spira, A., Joshua, A. M., Powderly, J., et al. (2021) · Annals of Oncology

Monoclonal and Polyclonal Antibodies ResearchProtein Degradation and Inhibitors

Cited by 28

Data from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Duro-Sánchez, S., Nadal-Serrano, M., Lalinde-Gutiérrez, M., Arenas, E. J., Bernadó Morales, C., Morancho, B., Escorihuela, M., Pérez-Ramos, S., Escrivá-de-Romaní, S., Gandullo-Sánchez, L., et al. (2023)

HER2/EGFR in Cancer ResearchTelomeres, Telomerase, and Senescence

Cited by 0